Accueil   Diary - News   All news iDD Biotech : second milestone payment from Genmab for GEN1029 safety trial

iDD Biotech : second milestone payment from Genmab for GEN1029 safety trial

iDD Biotech receives second milestone payment from Genmab with enrolment of fifth patient in GEN1029 (Hexabody®-DR5/DR) safety trial
in patients with malignant solid tumors


Lyon, France – December 4, 2018 –iDD biotech, a French immuno-oncology company with a large pipeline of preclinical and clinical stage monoclonal antibodies, reports that it has received a second milestone payment after its partner, Genmab, started a Phase I/IIa trial of GEN1029 (HexaBody-DR5/DR5). This potent and innovative combination of two anti-DR5 antibodies was discovered and developed by iDD biotech, who established preclinical proof of concept in solid tumors with unmet medical needs.

 

Read the press release

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree